Humanitarian Access to Unapproved Interventions in Public Health Emergencies of International Concern

PLoS Medicine

Volumn 12, Issue 2, 2015, Pages

  Singh, Jerome Amir ^a,b  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX VACCINE; ANTIVIRUS AGENT; BCX 4430; OSELTAMIVIR; PERAMIVIR; UNCLASSIFIED DRUG; VIRUS VACCINE; ZANAMIVIR;

ARTICLE; DEATH; DISEASE COURSE; DRUG EFFECT; DRUG MARKETING; EBOLA VIRUS; EMERGENCY HEALTH SERVICE; EPIDEMIC; ETHICS; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ACCESS; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HUMAN; INFECTION CONTROL; INFLUENZA VIRUS A H1N1; INTERVENTION STUDY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PUBLIC HEALTH; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN MEDICINE; ALTRUISM; EBOLAVIRUS; EMERGENCY; EXPERIMENTAL THERAPY; HEALTH; HEMORRHAGIC FEVER, EBOLA; INTERNATIONAL COOPERATION; RELIEF WORK; VIROLOGY;

ALTRUISM; EBOLAVIRUS; EMERGENCIES; EPIDEMICS; GLOBAL HEALTH; HEMORRHAGIC FEVER, EBOLA; HUMANS; INTERNATIONAL COOPERATION; PUBLIC HEALTH; RELIEF WORK; THERAPIES, INVESTIGATIONAL;

EID: 84924405915     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001793     Document Type: Article

References (33)

1. World Health Organisation (2014) WHO Statement on the Meeting of the International Health Regulations Emergency Committee Regarding the 2014 Ebola Outbreak in West Africa. http://www.who.int/mediacentre/news/statements/2014/ebola-20140808/en/. Accessed 01 September 2014.
2. Mpoke Bigg M (2014) U.N. to miss Dec 1 Ebola target due to rising Sierra Leone cases. http://www.reuters.com/article/2014/11/24/us-health-ebola-un-idUSKCN0J81QQ20141124. Accessed 24 November 2014.
3. US Centres for Disease Control (2014) Questions and Answers on Experimental Treatments and Vaccines for Ebola. http://www.cdc.gov/vhf/ebola/outbreaks/guinea/qa-experimental-treatments.html. Accessed 01 September 2014.
4. World Health Organisation (2014) Ethical considerations for use of unregistered interventions for Ebola virus disease (EVD). Summary of the panel discussion. http://www.who.int/mediacentre/news/statements/2014/ebola-ethical-review-summary/en/. Accessed 01 September 2014.
5. Hamburg M (2014) FDA as part of a coordinated global response on Ebola. http://blogs.fda.gov/fdavoice/index.php/2014/10/fda-as-part-of-a-coordinated-global-response-on-ebola/#sthash.8MePlWDX.dpuf. Accessed 07 November 2014.
6. EMA (2014) Medicines regulators to work together internationally to find innovative solutions to facilitate evaluation of and access to potential new medicines to counter Ebola outbreaks. http://www.ema.europa.eu/docs/en_GB/document_library/Other/2014/09/WC500172161.pdf. Accessed 07 November 2014.
7. WHO (2014) Consultation on potential Ebola therapeutics and vaccines. Background document for participants. Draft. http://www.who.int/csr/disease/ebola/ebola-new-interventions-02-sep-2014.pdf?ua=1. Accessed 01 January 2015.
8. WHO (2014) African regulators’ meeting looking to expedite approval of vaccines and therapies for Ebola. http://www.who.int/medicines/news/AFR_reg_meet/en/. Accessed 07 November 2014.
9. US FDA (2014) 21 CFR 56.102(d) http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=56.102. Accessed 01 September 2014.
10. US FDA (2014) 21 CFR, Sec. 312.23 or Sec. 312.34. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=312. Accessed 01 September 2014.
11. US FDA (2014) 21 CFR 56.104(c). http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=56.104. Accessed 01 September 2014.
12. Dennis B, Bernstein L (2014) Two Americans who contracted Ebola in Africa received an experimental serum. http://www.washingtonpost.com/national/health-science/2014/08/04/dbc44a48-1c07-11e4-ae54-0cfe1f974f8a_story.html. Accessed 01 September 2014.
13. Nightingale SL, Prasher JM, Simonson S (2007) Emergency Use Authorization (EUA) to enable use of needed products in civilian and military emergencies, United States (July 2007). Emerg Infect Dis. http://wwwnc.cdc.gov/eid/article/13/7/06-1188. Accessed 25 November 2014.
14. US FDA (2010) Amended Authorizations of Emergency Use of Certain Antiviral Drugs Zanamivir and Oseltamivir Phosphate; Availability. A Notice by the Food and Drug Administration on 04/19/2010. https://www.federalregister.gov/articles/2010/04/19/2010-8603/amended-authorizations-of-emergency-use-of-certain-antiviral-drugs-zanamivir-and-oseltamivir#h-10. Accessed 01 September 2014.
15. US FDA (2005) Authorization of Emergency Use of Anthrax Vaccine Adsorbed for Prevention of Inhalation Anthrax by Individuals at Heightened Risk of Exposure Due to Attack With Anthrax. A Notice by the Food and Drug Administration on 02/02/2005. https://www.federalregister.gov/articles/2005/02/02/05-2028/authorization-of-emergency-use-of-anthrax-vaccine-adsorbed-for-prevention-of-inhalation-anthrax-by. Accessed 01 September 2014.
16. US FDA (2014) Emergency Situations (Medical Devices). http://www.fda.gov/MedicalDevices/Safety/EmergencySituations/ucm161496.htm#h7n9. Accessed 01 September 2014.
17. US Health and Human Services Department (2014) Declaration Regarding Emergency Use of In Vitro Diagnostics for Detection of Ebola Virus. https://www.federalregister.gov/articles/2014/08/12/2014-19026/declaration-regarding-emergency-use-of-in-vitro-diagnostics-for-detection-of-ebola-virus. Accessed 01 September 2014.
18. US FDA (2014) Ebola Virus Emergency Use Authorization. http://www.fda.gov/MedicalDevices/Safety/EmergencySituations/ucm161496.htm#ebola. Accessed 01 September 2014.
19. Beck JM, Azari ED, (1998) FDA, Off-label use, and informed consent: debunking myths and misconceptions. Food and Drug Law Journal 53: 71–104. 11795338
20. US FDA (1982) FDA Drug Bulletin 4–5. Cited in 59 Fed. Reg. 59,820, 59,821 (18 Nov 1994).
21. Fedson DS, Opalaug SM (2014) Can Statins Help Treat Ebola? http://www.nytimes.com/2014/08/16/opinion/can-statins-help-treat-ebola.html?_r=0. Accessed 01 September 2014.
22. Kaneko K, Uetake T (2014) Japan could offer unapproved Ebola drug. http://www.reuters.com/article/2014/08/25/us-health-ebola-japan-idUSKBN0GP05X20140825. Accessed 01 September 2014.
23. Reuters (2014) First French Ebola patient leaves hospital. http://www.reuters.com/article/2014/10/04/us-health-ebola-france-idUSKCN0HT0D720141004. Accessed 01 September 2014
24. US FDA (2014) 21 CFR 312.42. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=312. Accessed 01 September 2014.
25. Tekmira (2011) Tekmira Pharmaceuticals Receives Approval from FDA to Initiate TKM-Ebola Phase 1 Clinical Trial. http://investor.tekmirapharm.com/releasedetail.cfm?ReleaseID=627019. Accessed 01 September 2014.
26. CBC News (2014) B.C.’s Tekmira gets FDA approval to fast track Ebola drug. http://www.cbc.ca/news/business/b-c-s-tekmira-gets-fda-approval-to-fast-track-ebola-drug-1.2731250. Accessed 01 September 2014.
27. Tekmira (2014) FDA Modifies Tekmira’s TKM-Ebola Clinical Hold to Partial Hold enabling use of Tekmira’s investigational therapeutic in Ebola-Infected patients. http://investor.tekmirapharm.com/releasedetail.cfm?ReleaseID=865208. Accessed 01 September 2014.
28. US FDA (2014) 21 CFR 314. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=314&showFR=1&subpartNode=21:5.0.1.1.4.9. Accessed 01 September 2014.
29. US FDA (2014) 21 CFR 314.610. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=314&showFR=1&subpartNode=21:5.0.1.1.4.9. Accessed 01 September 2014.
30. US FDA (2012) FDA approves raxibacumab to treat inhalational anthrax. First monoclonal antibody approved using the Animal Efficacy Rule. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm332341.htm. Accessed 01 September 2014.
31. Sullivan NJ, Martin JE, Graham BS, Nabel GJ, (2009) Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat Rev Microbiol 7(5): 393–400. doi: 10.1038/nrmicro2129 19369954
32. Warren TK, Wells J, Panchal RG, Stuthman KS, Garza NL, et al. (2014) Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature 508: 402–405. doi: 10.1038/nature13027 24590073
33. Globe Newswire (2014) BioCryst Receives Additional NIAID Funding to Conduct a Non-Human Primate Study of BCX4430 in Ebola Virus Disease. http://investor.shareholder.com/biocryst/ReleaseDetail.cfm?ReleaseID=868302. Accessed 01 September 2014.